In the UK, there are currently no national guidelines approving medical cannabis for dementia symptoms such as agitation, anxiety, or sleep disturbance. According to NICE guidance NG144, cannabis-based medicinal products (CBPMs) should only be prescribed by specialist clinicians for a limited number of conditions, specifically, severe epilepsy, chemotherapy-induced nausea, and spasticity associated with multiple sclerosis. Dementia is not among the approved indications.
NICE reaffirmed this position in 2024, noting that evidence for cannabinoids in cognitive decline and behavioural symptoms remains “insufficient and low quality.” Most available studies are small-scale, short-term, or observational, making it difficult to establish consistent safety or efficacy outcomes. The guidance further advises clinicians not to issue unlicensed CBPMs outside established care frameworks without specialist supervision and documented justification.
What NHS England and MHRA Say
NHS England’s 2023 CBPM Policy states that only doctors on the GMC Specialist Register may prescribe medical cannabis, and only after considering all licensed treatment options first. Prescribers must also demonstrate sufficient knowledge of the patient’s health, whether through in-person or telehealth consultation, ensuring that assessments meet full clinical governance standards.
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates CBPMs as unlicensed medicines, meaning prescribers carry additional responsibility for patient safety. The MHRA requires prescribers to comply with the Human Medicines Regulations 2012, ensuring secure prescription transfer, verified dispensing through registered pharmacies, and maintenance of named-patient records.
Although dementia is not an authorised condition, the MHRA supports the collection of prescribing data through the Medicinal Cannabis Patient Registry, launched in 2022. This registry includes both in-person and telehealth follow-up data, supporting long-term pharmacovigilance.
Research Evidence: Still Early and Limited
Evidence on cannabis use in dementia remains sparse and mixed. A 2022 Frontiers in Aging Neuroscience study explored oral THC: CBD treatment for agitation and rigidity among older adults in care homes. While the treatment appeared safe and modestly effective, the study did not assess long-term cognitive outcomes.
A 2025 PubMed study focusing on adults over 50 receiving telehealth-based cannabis care found improvements in anxiety and pain, though monitoring cognitive side effects remotely was challenging. Likewise, a 2025 University of Maryland trial examined cannabinoids for agitation in end-of-life dementia care, showing early signs of improved comfort and reduced psychotropic medication use.
A 2024 BMJ commentary cautioned that while teleconsultations have improved access to CBPMs, dementia-related prescribing remains off-label and ethically complex. Clinicians are advised to document risk–benefit discussions and ensure multidisciplinary involvement when considering unlicensed cannabis use.
Ethical And Regulatory Considerations
National policy frameworks place strong emphasis on clinical justification and patient safety. The GMC’s telemedicine standards state that clinicians must know the patient “well enough” before prescribing any controlled drug, including CBPMs. Private telehealth clinics must meet the same Care Quality Commission (CQC) standards as physical clinics, maintaining data protection and NHS GP communication.
For dementia, where symptoms can fluctuate and cognitive capacity varies, remote-only assessments may not meet these ethical or practical requirements. Multidisciplinary evaluation, often involving psychiatry, neurology, or geriatric medicine, remains the standard of care before any off-label cannabis use is considered.
How Other Countries Are Approaching the Issue
Internationally, several countries have explored medical cannabis for dementia-related symptoms, often under research or compassionate-use frameworks.
- Canada’s Health Canada report (2023) supports tele-triage systems for older adults using cannabinoids for agitation and pain but stresses clinician oversight.
- Israel’s 2024 cohort data show improved agitation and sleep among dementia patients in supervised programmes, though similar systems are not yet adopted in the UK.
These findings highlight growing international interest but also underline the lack of consensus and standardisation.
Clinical Bottom Line
- There are no national UK guidelines approving cannabis prescribing for dementia.
- NICE and NHS England restrict CBPM use to specific conditions only.
- Any use in dementia is off-label and requires a GMC-registered specialist with clear documentation.
- Evidence suggests potential benefits for agitation, but safety data remains limited.
- Ethical practice demands in-person or hybrid assessment, not online-only certification.
Role Of AlleviMed
Information services like AlleviMed help people understand the UK’s regulated medical cannabis framework. They explain eligibility criteria, prescribing pathways, and the role of specialists but do not issue prescriptions or make treatment recommendations. For individuals researching cannabis and dementia, AlleviMed’s educational materials clarify the difference between evidence-based use and unproven therapies.
Takeaway
In the UK, there are no approved national guidelines supporting the use of medical cannabis for dementia. NICE and NHS England continue to prioritise licensed treatments with proven benefit, while research into cannabinoids remains early. Any prescribing must be specialist-led, ethically justified, and closely monitored. As evidence evolves, the focus remains on safety, accountability, and informed decision-making for older adults and their carers.
